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ABSTRACT
The effect of ABO-incompatibility on transplantation outcome remains a controversial issue, with many of the
reported studies showing conflicting results. In this study, we evaluate: the association between ABO-
incompatibility and myeloid engraftment; the incidence and severity of acute and chronic graft-versus-host
disease (GVHD); non-relapse mortality (NRM); GVHD-associated mortality, relapse and overall survival
(OS). Our study includes 221 patients with malignant diseases treated in the same institution with the same
reduced intensity regimen. Other variables known to affect the transplantation outcome such as age, disease,
disease risk, and donor characteristics were well-balanced between ABO-matched and ABO-mismatched trans-
plants. Analysis of our data shows increased incidence of NRM during the first months after transplantation in
the groups of patients with major and minor ABO-incompatibility. Although neither incidence nor severity of
GVHD differed significantly among the different groups, we found increased mortality associated with
GVHD in the major ABO-incompatible groups. Long-term OS and relapse rate were not different, although
we observed a trend for decreased OS during the first year post transplantation in the group of patients with
major ABO-incompatibility. Our study showed that ABO-incompatibility has an adverse impact on the trans-
plantation outcome.
 2008 American Society for Blood and Marrow Transplantation
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The ABO blood group system discovered by Karl
Landsteiner in 1900 is one of the most important dis-
coveries in clinical medicine; it resulted in the intro-
duction of safe blood transfusions [1]. Allogeneic
bone marrow transplantation (BMT) or peripheral
blood stem cell (PBSC) transplantation has a high
curative potential in various hematological malignan-
cies, as well as in various inherited non-malignant dis-
orders. Although major ABO-incompatibility is
a serious barrier to solid organ transplantation, alloge-
neic BMT can be performed successfully across ABO-
mismatching between the donor and the recipient [2].
ABO-mismatching can be classified as follows: major
ABO-incompatibility is characterized by the presence
of anti-donor isohemagglutinins (e.g. A to O); minor
ABO-incompatibility by the ability of the transplanted
marrow to produce anti-host isohemagglutinins (e.g.
O to A); and bi-directional incompatibility by a combi-
nation of both (e.g. A to B) [2]. BMT across major
ABO-incompatibility can be accomplished following
elimination of red blood cells (RBC) prior to infusion
of stem cells. In the earliest days of allogeneic BMT
there was significant concern that ABO-mismatching
might lead to increased complications such as graft
rejection, graft-versus-host disease (GVHD), and/or409
410 I. B. Resnick et al.severe hemolytic reactions. Early studies suggested
that ABO-mismatched allogeneic BMT fared nearly
as well as ABO identical transplants with the exception
of occasional delayed RBC engraftment because of
prolonged hemolysis or pure red cell aplasia (PRCA).
However, these early studies were based on a small
number of patients and were performed decades ago
using myeloablative conditioning [3,4]. In contrast,
recent studies evaluating the significance of ABO-
mismatching gave conflicting results, and this issue re-
mains controversial [5,6]. In particular, several lines of
evidence suggest that ABO-incompatible stem cell
transplantation (SCT) may be associated with an in-
creased risk of GVHD and treatment related mortality
(TRM) [7]. The most recent multi-center assessment
of 3,103 patients who received conventional myeloa-
blative BMT for leukemia did not show any substantial
effect of ABO-incompatibility on the outcome [8].
Moreover, this issue is further complicated by recent
developments in the area of allogeneic SCT. PBSC is
being increasingly used instead of marrow because it
allows more rapid hematologic and immune reconsti-
tution. In contrast to bone marrow, PBSC contains
high numbers of T and B lymphocytes, as well as eryth-
rocyte precursors. Indeed, in PBSC transplantation,
delayed massive and fatal immune hemolysis from
rapid alloantibody production by the high number of
donor passenger B lymphocytes has been reported in
cases of minor or bi-directional ABO incompatibility
[9-11]. Also, in recent years, successful SCT has been
established following non-myeloablative (NST) or
reduced intensity regimens (RIC) [12-14]. The RIC
related toxicity associated with these so-called ‘‘mini-
transplants’’ resulted in the extended application of
allogeneic SCT to older patients with concurrent
co-morbidities, formerly considered ineligible for con-
ventional myeloablative SCT. Recent studies evaluat-
ing the significance of ABO-incompatibility in the
setting of NST (RIC), resulted in controversial find-
ings [15,16].
In the present study, we analyzed the effects of
ABO-mismatching in a group of 221 patients with
malignant disorders treated with the same RIC regi-
men in a single institution.
PATIENTS AND METHODS
Patients
We analyzed 221 consecutive patients with malig-
nant diseases, referred to the Department of Bone
Marrow Transplantation and Cancer Immunotherapy
of the Hadassah University Hospital in Jerusalem
between 1996 and 2005, and treated with the same
RIC regimen. The study protocol was approved by
the ethical committee of our hospital. All patients
signed informed consent agreements. The patients
were divided into the following 3 groups accordingto the ABO status between donor and recipient: Group
1, patients transplanted from ABO-matched donors
(n5127); Group 2, patients transplanted from donors
with minor ABO-incompatibility (n538); Group 3,
patients transplanted from donors with major ABO-
incompatibility, or from donors with bi-directional
incompatibility (n556). Characteristics of the patients
are listed in Table 1.
Transplantation Procedure
Conditioning regimen. For 221 patients with
malignant disease, allogeneic SCT was performed using
the sameRICprotocol.Conditioningconsistedoffludar-
abin 30mg/m2/day x 6, oral busulfan 4mg/kg/day (or i.v.
busulfex 3.2 mg/kg/day) x 2, and antithymocyte globulin
(ATG) (Fresenius) 10 mg/kg/day x 4. Oral busulfan was
given to 163 patients, whereas 58 patients were treated
with the intravenous formulation. The day of a first mar-
row infusion was designated as day (d) 0.
GVHD prophylaxis. All patients received GVHD
prophylaxis with cyclosporine A (CSA) with an initial
i.v. dose of 3 mg/kg or equivalent oral dose of 6 mg/kg
with subsequent control of serum levels and renal
function tests, initially from d-1 and subsequently
from the d-4.
Donors. The donors were HLA-A, -B, -C and high
resolution -DR fully matched siblings in 149 cases,
matched unrelated donors in 50 cases, and matched
non-sibling family members in 4 of the cases. One-
locus mismatched family members were donors in
12 patients, whereas one-locus mismatched unrelated
donors were used in 6 cases. PBSC was the source of
stem cells in 201 patients; PBSC in combination with
BM was the source for 8 patients; BM alone was used
in 20 cases. BM was collected from iliac crest under
epidural, spinal, or general anesthesia. For PBSC col-
lections, donors were injected subcutaneously with
granulocyte-colony stimulating factor (G-CSF;Neup-
ogen , 5 mg/kg twice daily for 5 days) and mobilized
PBSC were collected on days 5 and 6.
Supportive care. All patients were treated in
HEPA-filtered positively pressured rooms. Prior to
transplantation patients received acyclovir (1500mg/m2
per day) for prophylaxis of herpes simplex virus (HSV)
and cytomegalo virus (CMV) infection. Patients trans-
planted from alternative donors received ganciclovir
10 mg/kg for 5 days before BMT. CMV infections
(diagnosed by 2 successive positive PCRs or 1 positive
CMV pp65 antigenemia) were treated with ganciclovir
10mg/kg/day.TMP/SMX (10mg/kg/d trimethoprim)
was given to all patients from the beginning of condi-
tioning until d-2 and after engraftment (absolute neu-
trophil count (ANC) .0.75x109/L) twice a week for 6
months as a preventive measure against Pneumocystis
carinii.
Definitions. Day of neutrophil engraftment was
defined as the first of 3 consecutive days with
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ABO Matched ABO Minor Mismatched ABO Major Mismatch Significance (chi-square)
Number of Patients: 127 38 56
Age (Median) 40 38 41 NS (P 5 .70)
Sex (M:F) 81:46 28:10 33:23 NS (P 5 .33)
Disease:
ALL 11 5 3 NS (P 5 .35)
AML 34 12 17
CML 23 8 7
NHL 34 4 10
MDS/MF 10 5 8
Other 15 4 11
Disease Status:
Low risk 37 11 15 NS (P 5 .95)
High risk 90 27 41
Donor:
HLA-matched siblings 91 20 38 NS (P 5 .29)
Other HLA-matched relatives 3 0 1
Matched unrelated donors 25 13 12
Mismatched donors (related/unrelated) 8 (6/2) 5 (2/3) 5 (4/1)
Female to male 37 10 18 NS (P5.83)ANC.0.5x109/L. Day of platelet engraftment was
defined as the first of 3 days with platelets (PLT)
.20x109 /L without any transfusion support. For
acute and chronic GVHD (aGVHD, cGVHD) diag-
nosis and staging, standard previously published crite-
ria were used [17,18]. The overall peak grade of
aGVHD and cGVHD was reported in our study for
all the statistical evaluations. Evaluable for aGVHD
analysis were all patients that had a successful engraft-
ment and survived for at least 4 weeks, whereas evalu-
able for cGVHD analysis were all patients who
survived for 100 days. Non-relapse mortality (NRM)
was defined as mortality not directly associated with
relapse or progression of the original disease. Deaths
from GVHD provoked by immunotherapeutic ap-
proaches such as donor leukocyte infusions (DLI)
given for disease relapse or progression were not clas-
sified as NRM. GVHD-related mortality was defined
as mortality associated with GVHD either directly or
indirectly. Death from infection in a patient treated
with an immunosuppressive regimen for GVHD was
considered a GVHD-related death. Patients were
stratified to high or low risk categories according to
the disease status prior to the transplantation. Namely,
patients with acute myelogenous leukemia (AML) or
acute lymphoblastic leukemia (ALL) in first complete
remission, chronic myelogenous leukemia (CML) in
first chronic phase, myelodysplastic syndrome (MDS)
without excess of blasts (RA or RARS), and non-
Hodgkin lymphoma (NHL), Hodgkin disease (HD)
or multiple myeloma (MM) without chemorefractory
disease were classified as low-risk patients. All other
patients were classified as high-risk patients [19,20].
Survival was calculated from the time of transplanta-
tion until the time of death from any cause.Statistical analysis. For statistical analysis and
graphic data representation we used SPSS software,
version 12.0 for Windows. Assessments of median
(M), average (X), standard deviation, and Student’s
t-test with two tailed distribution were used as para-
metric criteria, whereas categorical data were com-
pared by c2 or Fisher exact tests. Logistic regression
analysis was used to evaluate the relative contribution
of various predictors to the differences of categorical
parameters, whereas linear regression analysis was
used to evaluate the relative contribution of parametric
variables. Cox’s regression and Kaplan-Meier models
were used for survival analysis.
RESULTS
The median follow-up period was 12 months with
a range of 2 to 114 months. Factors known to affect the
transplantation outcome such as age, disease, disease
risk, donor status, sex disparity between donor and
recipient, female donor to male recipient, were ana-
lyzed and were found to be well-balanced among the
3 groups of patients (Table 1).
Engraftment
Neutrophil and platelet engraftment were not dif-
ferent among the 3 groups. Neutrophil engraftment
was achieved in a median of 16 days in all 3 groups.
Platelet engraftment was achieved in a median of 12,
13, and 13 days in the ABO-matched, major ABO-
mismatched, and minor ABO-mismatched group,
respectively. No differences in the platelet and RBC
transfusion requirements were found between the 3
groups of patients either (data not shown). In the
group of major ABO-mismatch, 1 case of PRCA, and
412 I. B. Resnick et al.1 case of prolonged hemolysis were observed; in the
minor ABO-mismatch group, 1 case of transient
hemolysis was observed. The rate of rejection was
very low in our study (2.7%). Six of 221 patients
rejected their grafts; 5 in the group of ABO-match
and 1 patient in the group of major ABO-mismatch.
Three of 6 patients who rejected the graft had been
transplanted from matched unrelated donors, whereas
1 patient was transplanted from his one-locus HLA-
mismatched mother. The rate of rejection did not
vary among the 3 groups (P ..50).
GVHD
In the ABO-matched group, 116 patients were
evaluable for aGVHD. Among them aGVHD grade
II-IV, and III-IV were observed in 40 (34%), and 28
(24%) patients, respectively. Of 52 evaluable patients
in the major ABO-mismatched group, 23 (44%), and
19 (36%) patients developed aGVHD grade II-IV,
and III-IV, respectively. In the minor ABO-mis-
matched group among 31 evaluable patients, 12
(39%), and 9 (29%) developed aGVHD grade II-IV
and III-IV, respectively. We observed a trend
(P \.10) for increased incidence of severe aGVHD
grade III-IV in the ABO-mismatched group (36%)
in comparison with the ABO-matched group (24%)
(Figure 1).
In the ABO-matched group, 100 patients were
evaluable for cGVHD. Among them, 42 (42%) devel-
oped cGVHD; the cGVHDwas extensive in 27 (27%).
Among 39 evaluable patients in the major ABO-
mismatched group, 15 (38%) developed cGVHD,
and the cGVHD was extensive in 10 (26%). In the
minor ABO-mismatched group, the cumulative inci-
dence of cGVHD was 54% (13 of 24 evaluable
patients), whereas extensive cGVHD was observed in
7 (29%) patients. The differences in the incidence
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Figure 1.Cumulative incidence of acute GVHD (aGVHD): there is
a trend for more severe aGVHD grade III-IV in ABO major mis-
matched (MM) group compared to ABO matched group
(P 5.098). (Here and in subsequent figures, absolute numbers of
patients are shown in the appropriate fields.)and severity of cGVHD between the 3 groups were
not significant (P 5.68).
Non-relapse Mortality
In the ABO-matched group, the 1-year NRM was
22% (29 deaths among 127 patients). In the major
ABO-mismatched group, the 1-year NRM was 39%
(22 deaths among 56 patients). In the minor ABO-
mismatched group the 1-year NRM was 31.6% (12
deaths among 38 patients). The 1-year NRM was
significantly increased in the major-ABO (P 5 .023)
and minor-ABO (P 5 .045) mismatched groups in
comparison with ABO-matched group (Figure 2).
NRM at 3 months was also significantly increased in
the ABO-mismatched groups in comparison with the
ABO-matched group (P\ .01).
aGVHD and cGVHD associated Deaths
We tried to evaluate the cause of increasedNRM in
ABO-mismatched groups. Therefore, we analyzed the
incidence of GVHD-associated deaths in the 3 groups
of patients. In ABO-matched group, 10 of 127 patients
died during the first year due to aGVHDand cGVHD-
related causes (7.9%). In the major ABO-mismatched
group, 11 of 56 (19.6%) patients died from GVHD,
whereas in the minor ABO-mismatched group 5 of 38
(13.5%) patients died from the same causes. Distribu-
tion analysis showed that in comparison with the
ABO-matched group the incidence of GVHD associ-
ated deaths was significantly higher (P 5.021) in the
major ABO-mismatched group (Figure 3).
Acute GVHD-associated Deaths
We tried to evaluate the response to therapy and
the mortality from aGVHD between the 3 groups as
well. In the ABO-matched, major ABO-mismatched,
and minor-ABO-mismatched groups, 7.5%, 30%,
and 25% of patients with aGVHD grade II-IV died
from aGVHD, respectively (P 5.05). Significantly
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Figure 2. Non-relapse mortality is higher in ABO mismatched
groups: P 5.045 for minor and P 5.023 for major mismatched
groups, respectively.
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had aGVHD that was resistant to treatment and died
from this complication in comparison with patients
in the ABO-matched group (P 5.014). Also, a trend
for increased aGVHD-related mortality was observed
among the minor ABO- mismatched group.
Relapse, Other Causes of Death, and Overall
Survival
Within a median follow up of 12 months, 35 pa-
tients in the ABO-matched group died from relapse
or disease progression, whereas 10 and 7 patients died
from the same cause in the major ABO-mismatched
and minor ABO-mismatched group, respectively. The
relapse rate was not significantly different between
the 3 groups. In addition, theminormismatched group
demonstrated a slightly higher incidence of deaths
associated with infectious complications, such as sepsis
including adult respiratory distress syndrome (ARDS)
and development of multiorgan failure (MOF), as
well as opportunistic infections, for example, invasive
aspergillosis (37% vs. 22% and 28% in matched and
major mismatched groups, respectively). These differ-
ences in distribution are significant according to chi-
square test (P 5.037, Figure 4). Except for a trend
towards decreased overall survival (OS) in the major
ABO-mismatched group during the first year after
BMT, OS was not significantly different between the
3 groups (Figure 5).
Results of Multifactorial Analysis
OS,NRM in 3 and 12months, and development of
aGVHD and cGVHD were analyzed by a multifacto-
rial model. Independent variables such as patient’s age,
female-to-male transplantation, disease risk group,
aGVHD and cGVHD presence, grade (severity) and
timing were included in the model. Using logistic re-
gression and Cox’s analysis, we confirmed that ABO-
matching characteristics remained insignificant for
OS (P 5.098), whereas major poor prognostic factors
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Figure 3. GVHD-associated mortality is higher in the ABO major
mismatched group compared with the ABO matched group
(P 5.021).were disease risk category (P 5.0001), aGVHD,
especially grade IV (P \.0001) as well as older age
(P 5.049, all according to Cox’s analysis). At the
same time, ABO-mismatching remains a significant
predictor factor for NRM and GVHD- associated
deaths at 3 or 12 months after BMT, as well as for
development of cGVHD (P 5.031).
DISCUSSION
The discrepancy of the results between different
studies devoted to effects of ABO-incompatibility on
transplant outcome can be explained in several ways. Re-
ported studies are different inmany aspects thatmay aug-
ment or reduce the significance of ABO-incompatibility.
Some of the factors can be summarized as follows:
1) Variance in the intensity of the preparative regi-
men. RIC, in contrast with myeloablative prepara-
tive regimens, usually establishes a transient state of
mixed chimerism that gradually converts to com-
plete donor chimerism, either spontaneously or
after manipulations such as withdrawal of cyclo-
sporine or DLI. From a theoretical point of view,
RIC regimens are anticipated to be associated
with increased incidence of complications related
to major ABO-incompatibility, because of the de-
layed elimination of host anti-donor B-lympho-
cytes. Indeed, delayed donor cell chimerism and
increase incidence of PRCA were found by Bolan
et al [21] in a group of patients with major ABO-
mismatched grafts, who were treated with a non-
myeloablative conditioning.
2) Difference in the source of stem cells. PBSC grafts,
in contrast to bone marrow, contain at least 1 log
more B-lymphocytes. This observation may be of
importance in cases of minor ABO-mismatches
because passively transferred donor B-lymphocytes
can lead to production of significant amounts of
anti-host isohemagglutinins [9,11].
3) Differences in the GVHD prophylaxis regimens.
CSA, in contrast with methotrexate (MTX), does
not have any cytolytic effect on lymphocytes and
is less efficient in preventing the activation of B
than of T-lymphocytes. It has been suggested that
CyA used alone, without the addition of MTX,
can be associated with increased incidence of pro-
longed hemolysis or PRCA in cases of ABO-incom-
patibility [22,23]. Also the effect, if any, of ABO-
mismatch on the transplantation outcome can be
altered by the use of antibodies given in vivo or ex
vivo for prevention of GVHD. Alemtuzumab, a hu-
manized monoclonal antibody (mAb) with reactiv-
ity against the pan-lymphocyte antigen CD52, is
effective in promoting apoptosis of T and B lym-
phocytes through complement-dependent and
antibody-dependent cell-mediated cytotoxicity
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Figure 4. Distribution of major causes of death is different in ABO matched and mismatched groups, P 5.037 according to chi-square test
(ARDS indicates adult respiratory distress syndrome; MOF, multi-organ failure).mechanisms. Peggs et al [24] did not observe any
cases of PRCA or hemolysis in a group of 19 pa-
tients transplanted from major ABO-mismatched
donors. In their study, alemtuzumab was used as
part of the conditioning regimen.
4) Lastly, the significance of ABO-incompatibility can
be masked by other factors known to affect the
transplantation outcome such as age, diagnosis, dis-
ease status pre-transplantation, donor characteris-
tics, sex disparity between donor and recipient,
and minor differences in supportive treatment at
different centers.
All the patients included in this study were treated
in the same institution with the same preparative reg-
imen, were given the same GVHD prophylaxis regi-
men, and received the same infection prophylaxis
protocols. Other variables known to affect transplanta-
OS (ABO matched vs minor vs major mismatched)
0%
20%
40%
60%
80%
100%
0 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108114
months after BMT
M
6
ABO matched
ABO minor 
mismatched
ABO major 
mismatched
Figure 5. Kaplan-Meier probability of overall survival according to
the degree of ABO incompatibility. (M and dotted line indicate
median survival.)tion outcomewere analyzed and were found to be well-
balanced among the different ABO groups.
Our results show that in the setting of RIC, ABO-
incompatibility does not have any effect on the rate of
neutrophil and megakaryocyte engraftment. Because
rejections were extremely rare in our study population,
the effect, if any, of ABO-mismatch on the rate of
rejection could not be evaluated. Although exceptional
cases of delayed engraftment, higher transfusion re-
quirement, or even rejections have been reported in
association with major ABO-mismatch, results from
previous studies are in accordance with our findings
[8,20,25-27]. These observations are in agreement
with laboratory data showing that ABO blood group
antigens are highly expressed on the surface of
erythroid progenitors, whereas they are expressed on
only 5% of more primitive progenitors such as
GEMM-CFU [28]. In our study, the incidence of pro-
longed hemolysis or PRCA in the group of patients
with major ABO-mismatch was very low (3.5%).
Similar to our study, Kanda et al [29] showed that
the use of a reduced intensity regimen consisting of
a purine analog and busulfan was not associated with
increased incidence of immunohematologic complica-
tions in major ABO-mismatched transplantations [27].
This observation may be explained by the hypothesis
that the combination of busulfan with a purine analog
has high activity against plasma cells resulting in the
early elimination of anti-donor isohemagglutinins.
In this study, we observed increased incidence of
severe aGVHD in the group of patients with major
ABO-incompatibility, although this increased rate
did not reach statistical significance. The results of
other studies evaluating this issue are conflicting.
Goldman et al [30] did not observe any significant
effect of ABO-incompatibility on the incidence of
aGVHD. However, a study performed by Bacigalupo
et al [31] showed more aGVHD in the group of
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Type of transplantation Conventional BMT (Seebach et al., 2005 [8]) RIC (our data)
Number of patients 3,103 (232 centers) 221 (single center)
Cells’ source BMT from matched donors PBMC in 201 and BMT in 20 from matched donors
Median follow-up 54 mos 77 mos
Engraftment Slower for neutrophyls and RBC in major ABO
incompatibility group
No difference for WBC, platelets and RBC
Rejection No data No difference
Acute GVHD Trend to higher severity in bi-directional mismatched Trend to higher severity in major mismatched
Chronic GVHD Similar Higher
OS Similar Similar
NRM Similar Higher in 3 mos in mismatched, in 1 yr in major
mismatched, and a higher number of GVHD
associated deathspatients with minor ABO-mismatch. Also, in more re-
cent studies, Stussi et al [32], observed more GVHD,
and Seebach et al [8] greater severity of aGvHD after
bidirectional ABO-incompatible transplantations.
Comparison with the latest study published for the
GVHD Working Committee of the Center for Inter-
national Blood and Marrow Transplant (IBMT) Re-
search is presented in Table 2. This table shows that
there are some differences between cohorts of patients
who underwent myeloablative (IBMT study [8]) or
non-myeloablative (our study) transplantation. The
most interesting finding of our study was the observa-
tion of significantly increased NRM in 3 and 12
months in the groups of patients with major and minor
ABO-incompatibility. More importantly, in the ABO
major mismatched group, the aGVHD and
cGVHD-associated mortality was also significantly
increased, suggesting that ABOmajor mismatched pa-
tients suffered from more resistant GVHD. The in-
creased NRM resulted in a trend for decreased
1-year OS in the group of patients with major ABO-
mismatch. Taken together, these data raise the possi-
bility of an association between ABO-mismatch and
severe GVHD resistant to treatment.
Our analytical findings and the observations from
previous studies that showed an adverse impact of
ABO-incompatibility on transplantation outcome
raised significant questions about the pathogenetic
mechanisms of this association. Several explanations
have been proposed. Hemolysis observed in the major
ABO-mismatch setting can lead to secretion of cyto-
kines resulting in activation of donor anti-host allo-
reactive T-cell clones. However, in our study, we did
not observe an increased incidence of hemolytic reac-
tions. In this regard, it is of interest that ABO-antigens
have a broad range of tissue distribution, including
endothelial cells and von-Willebrand factor [33]. Do-
nor anti-host isohemagglutinins produced after minor
or bi-directional ABO-mismatched transplantations
can attack host endothelial cells expressing blood
group antigens triggering GVHD. Insight into the
system of ABO-glycosyltransferases may offer anotherexplanation of the association between ABO-blood
group system and transplantation outcome. The A
and B antigenic structures of the ABO-blood group
system are carbohydrates that are synthesized by
transfer of different sugars (GalNAc and Gal) to the
H-substrate. The transfer of different sugars is accom-
plished by proteins with glycosyltransferase activity.
ABO-genes are highly polymorphic and different
alleles encode for glycosyltransferases with different
enzymatic activity. Blood group A phenotype is associ-
ated with allelic variants that encode for proteins with
A-transferase activity, while B-phenotype is associated
with alleles that encode for proteins with B-transferase
activity. Non-functional alleles code for proteins with-
out any enzymatic activity and therefore are associated
with O-phenotype [34]. Until now, approximately 100
different allelic sequences of ABO-glycosyltransferases
have been identified. However, only few of them are
detected with increased frequency in different individ-
uals [35]. From the above data one can conclude that
ABO-phenotypically mismatched individuals are also
mismatched at the genotypic level, while ABO-
phenotypic identity does not necessarily mean
genotypical identity. Recent studies showed that
ABO-glycosyltransferases might act as minor histo-
compatibility antigens (mHAgs). Eiz-Veisper and
colleagues [36] in an elegant study proved that peptides
derived from ABO-transferases are capable of stimu-
lating peptide-specific alloreactive T-cells from indi-
viduals lacking the peptide, while the opposite was
true for individuals expressing the specific peptide
sequence. ABO-phenotypically mismatched donor-
recipient pairs express, by definition, different ABO-
mHAgs, while matched pairs have a high likelihood
of being identical at the ABO-mHAgs level. These
data are in agreement with the observed association
of increased TRM, GVHD-related deaths in ABO-
mismatched transplants.
In conclusion, in our study, we found that ABO-
mismatch is associated with increasedNRM in the first
months post transplantation. In the major ABO-
mismatched patients, the increased NRM resulted
416 I. B. Resnick et al.frommore GVHD-related deaths. These results are in
accordance with many of the previous studies. Analysis
of large cohorts of transplantation patients will be
required to fully assess all the consequences of ABO-
mismatching in comparison with other factors. Based
on the above, practically speaking, the role of ABO-
matching in choosing an optimal donor, when more
than one is available, should not be underestimated.
Consideration of ABO-identity at the allelic level
should be included in future trials.
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